Perioperative Respiratory Care and Outcomes for Patients Undergoing High Risk Abdominal Surgery
Launched by UNIVERSITY OF BIRMINGHAM · Feb 4, 2020
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
The PENGUIN trial is a research study looking at how certain treatments before and during major abdominal surgery can affect the risk of serious infections like pneumonia and surgical site infections. This study will involve patients from low and middle-income countries, who will be randomly assigned to one of four groups. Some will use a special mouthwash called chlorhexidine before surgery, while others will not. Additionally, the amount of oxygen they receive during surgery will vary between groups. The goal is to see which combination helps reduce the chances of infections after surgery.
To participate in this trial, patients must be at least 10 years old and scheduled for an elective or emergency abdominal surgery that requires a significant incision (at least 5 cm long). Patients who are allergic to chlorhexidine, those undergoing certain types of surgery like caesarean sections, or those who cannot be contacted after leaving the hospital are not eligible. Participants will need to give their consent, which can be done by signing a form or using a fingerprint. This study is currently recruiting, and it aims to improve care and outcomes for patients undergoing high-risk surgeries.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Adults and children aged 10 years or over
- • Elective or emergency abdominal surgery via midline laparotomy with an anticipated abdominal incision of at least 5cm in length
- • Written informed consent of patient (signature or a fingerprint)
- Exclusion Criteria:
- • Patients undergoing caesarean section
- • Patients with a documented or suspected allergy to chlorhexidine
- • Patient unable to complete postoperative follow-up (not contactable after discharge)
- • Previous enrolment in PENGUIN within the past 30 days
- • American Society of Anesthesiologists (ASA) grade V patients (expected to die with or without surgery)
About University Of Birmingham
The University of Birmingham is a leading research institution in the UK, renowned for its commitment to advancing medical science and improving health outcomes through innovative clinical research. With a strong emphasis on collaboration, the university engages in multidisciplinary studies that leverage cutting-edge technology and expertise across various fields. Its dedicated clinical trial infrastructure supports rigorous investigation and the ethical conduct of research, ensuring that findings contribute meaningfully to the scientific community and public health. Through its initiatives, the University of Birmingham aims to translate research discoveries into tangible benefits for patients and healthcare systems alike.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Cape Town, , South Africa
Mumbai, , India
Porto Alegre, , Brazil
Porto Alegre, , Brazil
New Delhi, , India
Cape Town, , South Africa
Kolkata, , India
Lagos, , Nigeria
Bhubaneswar, , India
Ludhiana, , India
Veracruz, , Mexico
Botucatu, Sp, Brazil
Salvador, , Brazil
São José, , Brazil
Visakhapatnam, Andhra Pradesh, India
Srinagar, Jammu And Kashmir, India
Chinchpada, Maharashtra, India
Madhava Nagar, Manipal, Karnataka, India
Patiala, Punjab, India
Chandigarh, , India
Jodhpur, , India
Madhepura, , India
Mumbai, , India
Rishīkesh, , India
Vellore, , India
Belisario Domínguez, , Mexico
Benin City, , Nigeria
Gwagwalada, , Nigeria
Ibadan, , Nigeria
Ile Ife, , Nigeria
Ilorin, , Nigeria
Kaduna, , Nigeria
Kano, , Nigeria
Lagos, , Nigeria
Nnewi, , Nigeria
Cape Town, , South Africa
Paarl, , South Africa
Madhava Nagar, , India
Patients applied
Trial Officials
Rupert Pearse
Principal Investigator
Royal London Hospital
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials